February 2026 in “Psycho-Oncologie” Alopecia areata causes significant psychological distress in cancer patients, needing integrated care.
January 2026 in “Dermatology Practical & Conceptual” Triamcinolone acetonide is more effective than cryotherapy for hair regrowth in alopecia areata but has different side effects.
December 2025 in “International Journal of Research in Ayurveda and Pharmacy” Ayurvedic treatment successfully regrew hair in a 19-year-old with alopecia areata in 2 months.
December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology” DNCB is more effective than betamethasone for hair regrowth but has more side effects.
December 2025 in “Clinical Cosmetic and Investigational Dermatology” Early diagnosis and multidisciplinary care, including orthopedic surgery, can prevent long-term disability in IFAP syndrome.
September 2025 in “Dermatology and Therapy” Activated PRP effectively increases hair density and reduces hair loss in alopecia.
January 2025 in “EXPERIMENTAL ANIMALS” Stingless bee propolis may help regenerate hair follicles and improve pigment function in chemotherapy-induced hair loss.
October 2024 in “Journal of Education Health and Sport” Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.
September 2024 in “Egyptian Journal of Medical Human Genetics” Consider NF1 in newborns with rare congenital anomalies.
February 2024 in “Scientific reports” Four genes are potential markers for hair loss condition alopecia areata, linked to a specific type of cell death.
Screening for iron levels in patients with hair loss may help find a genetic iron overload condition early.
March 2022 in “Nepal Journal of Dermatology Venereology & Leprology” Methotrexate with steroids is slightly more effective than azathioprine with steroids for treating severe alopecia areata.
November 2020 in “Bali Medical Journal” PRP may help hair growth in alopecia areata without major side effects, but more research is needed.
April 2018 in “Journal of Investigative Dermatology” Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.
April 2018 in “Journal of Investigative Dermatology” Topical tofacitinib is effective in promoting hair growth for non-scarring alopecia.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
January 2005 in “Pediatric Dermatology” Alopecia areata in infants may be more common than previously thought.
Clinical signs don't match inflammation levels in lichen planopilaris and frontal fibrosing alopecia.
March 2021 in “Research Society and Development” A blue Staffordshire Bull Terrier had hair loss due to color dilution alopecia, confirmed by tests, but no treatment was pursued.
1 citations
,
May 2023 in “Revista Eletrônica Acervo Saúde” Alopecia after COVID-19 negatively impacts quality of life, especially vitality.
April 2023 in “Research Society and Development” Corticosteroids are safe and effective for treating Alopecia Areata.
September 2019 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” Isotretinoin at low doses effectively treats facial papules in frontal fibrosing alopecia.
Eclipta alba can be used in products to treat hair loss.
January 2018 in “Annals of Dermatology” Newspaper articles on alopecia are often inaccurate and sometimes mix up different types of hair loss.
218 citations
,
April 2012 in “British Journal of Dermatology” Guidelines suggest various treatments for alopecia areata, but leaving it untreated is also an option as 80% cases may recover on their own.
196 citations
,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
191 citations
,
May 2018 in “British journal of dermatology/British journal of dermatology, Supplement” Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.
164 citations
,
April 2008 in “Cochrane library” Current treatments for alopecia show no significant long-term benefits.
144 citations
,
July 2015 in “Clinical, Cosmetic and Investigational Dermatology” Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.
131 citations
,
October 2004 in “Clinical Cancer Research” Tempol is safe and may prevent hair loss from brain radiotherapy.